Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Viatris Inc. (VTRS)

10.71   0.24 (2.29%) 07-02 16:32
Open: 10.45 Pre. Close: 10.47
High: 10.74 Low: 10.28
Volume: 6,541,915 Market Cap: 12,984(M)
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.75 - 10.81 10.81 - 10.87
Low: 10.13 - 10.2 10.2 - 10.28
Close: 10.59 - 10.71 10.71 - 10.81

Technical analysis

as of: 2022-07-01 4:26:09 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 13.49     One year: 14.45
Support: Support1: 10.21    Support2: 8.49
Resistance: Resistance1: 11.55    Resistance2: 12.38
Pivot: 10.65
Moving Average: MA(5): 10.79     MA(20): 10.91
MA(100): 11.28     MA(250): 12.87
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 34.6     %D(3): 36.3
RSI: RSI(14): 45.1
52-week: High: 15.6  Low: 9.65
Average Vol(K): 3-Month: 11,629 (K)  10-Days: 9,246 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ VTRS ] has closed below upper band by 44.1%. Bollinger Bands are 59.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Sat, 02 Jul 2022
Presentation by VTR team at AWE - 'Building Disruptive Pilot Training with XR and Eye Tracking: VTR Case of Empowering Major Airlines' - Airline fleet Management

Sat, 02 Jul 2022
Ellevest Inc. Has $174000 Holdings in Ventas, Inc. (NYSE:VTR) - Defense World

Fri, 01 Jul 2022
Ventas (NYSE:VTR) Price Target Lowered to $61.00 at Mizuho - MarketBeat

Fri, 01 Jul 2022
2022-07-01 | NDAQ:VTRS | Press Release | Viatris Inc. - Stockhouse

Thu, 30 Jun 2022
Jefferies likes data center, tower, industrial, senior housing REITs (NYSE:VTR) - Seeking Alpha

Thu, 23 Jun 2022
Interesting VTRS Put And Call Options For August 5th - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 1,210 (M)
Shares Float 1,210 (M)
% Held by Insiders 0.2 (%)
% Held by Institutions 75.3 (%)
Shares Short 20,200 (K)
Shares Short P.Month 23,460 (K)

Stock Financials

EPS -1.73
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 17.47
Profit Margin (%) -7.1
Operating Margin (%) 16.5
Return on Assets (ttm) 3.1
Return on Equity (ttm) -5.9
Qtrly Rev. Growth 19.7
Gross Profit (p.s.) 6.4
Sales Per Share 14.78
EBITDA (p.s.) 5.1
Qtrly Earnings Growth 0
Operating Cash Flow 3,020 (M)
Levered Free Cash Flow 5,430 (M)

Stock Valuations

PE Ratio -6.23
PEG Ratio -2.5
Price to Book value 0.61
Price to Sales 0.72
Price to Cash Flow 4.29

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2022-03-15
Ex-Dividend Date 2022-02-22
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.